Current Opinion in Hematology, Nov 28, 2024
We recently wrote a review on the diverse models used to study myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), highlighting their applications and limitations in understanding disease biology and testing therapies. The article focuses on genetically engineered mouse models, human iPSC-derived systems, patient-derived xenografts, and engineered blood stem cells, emphasizing their contributions to advancing translational hematology research.
Science, Jul 09, 2021
We utilized CRISPR/Cas9-mediated genome editing in human primary disomic and trisomic hematopoietic stem cells to generate an in vivo model of Down syndrome associated leukemia evolution. This humanized model enabled us to study the mechanism of predisposition, preleukemia initiation and leukemic transformation in order to identify potential therapeutic targets of the disease.
Blood Cancer Discovery, Dec 12, 2024
Nature, Dec 12, 2024
Haematologica, Dec 12, 2024
Current Opinion in Hematology, Nov 28, 2024
Cell Stem Cell, Nov 13, 2023
Haematologica, Oct 02, 2023
Leukemia, Sep 21, 2022
Cell Rep, Mar 08, 2022
Cell Stem Cell, Aug 02, 2021
Science, Jul 09, 2021